{"id":"slow-itraconazole-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Itraconazole is a triazole antifungal that selectively targets fungal sterol synthesis by inhibiting the demethylation of lanosterol to ergosterol. The slow/modified-release formulation extends drug exposure and improves bioavailability compared to standard itraconazole formulations, allowing for more consistent antifungal activity. This mechanism is effective against a broad spectrum of fungi including Aspergillus, Candida, and other clinically important pathogens.","oneSentence":"Slow itraconazole tablet is a modified-release formulation of itraconazole that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in fungal cell membranes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:24.887Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Fungal infections (broad-spectrum including aspergillosis, candidiasis, and other systemic mycoses)"}]},"trialDetails":[{"nctId":"NCT05679388","phase":"PHASE1","title":"A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2023-02-13","conditions":"Prostate Cancer, Prostate Cancer Metastatic, Prostate Adenocarcinoma","enrollment":60},{"nctId":"NCT04035187","phase":"PHASE4","title":"Itraconazole Oral Absorption","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2020-02-10","conditions":"Fungal Infection","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["slow dissolving itraconazole tablet"],"phase":"marketed","status":"active","brandName":"slow itraconazole tablet","genericName":"slow itraconazole tablet","companyName":"University of Maryland, Baltimore","companyId":"university-of-maryland-baltimore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Slow itraconazole tablet is a modified-release formulation of itraconazole that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in fungal cell membranes. Used for Fungal infections (broad-spectrum including aspergillosis, candidiasis, and other systemic mycoses).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}